Claim to patent AIDS drug rejected
In a decision that will go a long way in soothing people living with HIV/AIDS (PLHAs), the Indian patent office today turned down the claim of a drug company to patent nevirapine. The drug is critical to HIV/AIDS treatment strategy, and is a crucial part of treatment for children affected by the virus. Patenting the drug would have meant limited access to HIV/AIDS treatment.